Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
Open Access
- 15 June 2024
- journal article
- research article
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 243, 108378
Abstract
No abstract availableKeywords
Funding Information
- Biogen Inc
This publication has 17 references indexed in Scilit:
- Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimodJournal of Neurology, 2022
- COVID‐19 Vaccine Response in People with Multiple SclerosisAnnals of Neurology, 2021
- Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapiesEBioMedicine, 2021
- Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditionsThe Lancet, 2021
- DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and FranceAnnals of Clinical and Translational Neurology, 2021
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple SclerosisJAMA Neurology, 2021
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessationJournal of Neuroimmunology, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosisAnnals of Neurology, 2011